PL364936A1 - Sposoby leczenia zaburzeń psychicznych z zastosowaniem bioaktywnych metabolitów gepironu - Google Patents

Sposoby leczenia zaburzeń psychicznych z zastosowaniem bioaktywnych metabolitów gepironu

Info

Publication number
PL364936A1
PL364936A1 PL00364936A PL36493600A PL364936A1 PL 364936 A1 PL364936 A1 PL 364936A1 PL 00364936 A PL00364936 A PL 00364936A PL 36493600 A PL36493600 A PL 36493600A PL 364936 A1 PL364936 A1 PL 364936A1
Authority
PL
Poland
Prior art keywords
gepirone
psychological disorders
treatment
bioactive metabolites
metabolites
Prior art date
Application number
PL00364936A
Other languages
English (en)
Other versions
PL200378B1 (pl
Inventor
Stephen J. Kramer
Louis F. Fabre
Edward H. Ruediger
Joesph P. Yevich
Original Assignee
Fabre-Kramer Pharmaceuticals, Inc.
Edward H. Ruediger
Yevich Joseph P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre-Kramer Pharmaceuticals, Inc., Edward H. Ruediger, Yevich Joseph P. filed Critical Fabre-Kramer Pharmaceuticals, Inc.
Publication of PL364936A1 publication Critical patent/PL364936A1/pl
Publication of PL200378B1 publication Critical patent/PL200378B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL364936A 1999-12-20 2000-12-18 Zastosowanie metabolitu gepironu do wytwarzania leku do poprawienia stanu psychologicznego u ssaka oraz kompozycja zawierająca metabolit gepironu PL200378B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17268499P 1999-12-20 1999-12-20
US09/709,741 US6534507B1 (en) 1999-12-20 2000-11-13 Methods for treating psychological disorders using bioactive metabolites of gepirone
PCT/US2000/034131 WO2001045687A2 (en) 1999-12-20 2000-12-18 Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Publications (2)

Publication Number Publication Date
PL364936A1 true PL364936A1 (pl) 2004-12-27
PL200378B1 PL200378B1 (pl) 2008-12-31

Family

ID=26868346

Family Applications (1)

Application Number Title Priority Date Filing Date
PL364936A PL200378B1 (pl) 1999-12-20 2000-12-18 Zastosowanie metabolitu gepironu do wytwarzania leku do poprawienia stanu psychologicznego u ssaka oraz kompozycja zawierająca metabolit gepironu

Country Status (20)

Country Link
US (1) US6534507B1 (pl)
EP (1) EP1242061B1 (pl)
JP (1) JP4236407B2 (pl)
KR (1) KR100602976B1 (pl)
CN (1) CN1411375A (pl)
AT (1) ATE294572T1 (pl)
AU (1) AU776409B2 (pl)
CA (1) CA2395458C (pl)
CZ (1) CZ300429B6 (pl)
DE (1) DE60019968T2 (pl)
ES (1) ES2241683T3 (pl)
HU (1) HU228963B1 (pl)
IL (2) IL150222A0 (pl)
MX (1) MXPA02006146A (pl)
NO (1) NO323304B1 (pl)
NZ (1) NZ519554A (pl)
PL (1) PL200378B1 (pl)
PT (1) PT1242061E (pl)
RU (1) RU2282448C2 (pl)
WO (1) WO2001045687A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295478A1 (en) * 2000-08-22 2002-03-04 Akzo Nobel N.V. Active metabolite of gepirone
US20040000689A1 (en) * 2002-06-28 2004-01-01 Erh-Kun Lai Dual-bit MONOS/SONOS memory structure with non-continuous floating gate
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
AU2003259086A1 (en) * 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Improved process for hydroxyazapirones
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050165233A1 (en) * 2003-11-18 2005-07-28 Mourad Hamedi Continuous process for producing hydroxyazapirones by oxidation
CA2585606A1 (en) * 2004-11-05 2006-05-18 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
KR20110013385A (ko) * 2008-05-08 2011-02-09 파브르-크래머 홀딩스. 인크 주의력 결핍 장애 및 성기능 장애의 치료를 위한 3-히드록시 게피론

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5185329A (en) * 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
KR100195656B1 (ko) * 1989-05-31 1999-06-15 로버트 에이.아미테이지 치료학적으로 유용한 2-아미노테트랄린 유도체
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
WO2001045687A3 (en) 2002-04-25
DE60019968D1 (de) 2005-06-09
MXPA02006146A (es) 2004-08-23
RU2002119400A (ru) 2004-01-27
CN1411375A (zh) 2003-04-16
EP1242061A2 (en) 2002-09-25
IL150222A0 (en) 2002-12-01
DE60019968T2 (de) 2006-02-02
HUP0301831A2 (hu) 2003-09-29
HU228963B1 (en) 2013-07-29
NO20022954L (no) 2002-06-19
JP2004500362A (ja) 2004-01-08
US6534507B1 (en) 2003-03-18
CZ20022137A3 (cs) 2003-03-12
EP1242061B1 (en) 2005-05-04
RU2282448C2 (ru) 2006-08-27
CA2395458A1 (en) 2001-06-28
PL200378B1 (pl) 2008-12-31
PT1242061E (pt) 2005-09-30
ES2241683T3 (es) 2005-11-01
WO2001045687A2 (en) 2001-06-28
IL150222A (en) 2009-09-22
ATE294572T1 (de) 2005-05-15
AU776409B2 (en) 2004-09-09
NO20022954D0 (no) 2002-06-19
NO323304B1 (no) 2007-03-05
AU2268701A (en) 2001-07-03
CZ300429B6 (cs) 2009-05-20
KR20020082470A (ko) 2002-10-31
JP4236407B2 (ja) 2009-03-11
NZ519554A (en) 2005-01-28
KR100602976B1 (ko) 2006-07-20
CA2395458C (en) 2009-05-12

Similar Documents

Publication Publication Date Title
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
AR027528A1 (es) Preparacion farmaceutica para el tratamiento de rinitis alergica y/o vasomotriz o conjuntivitis alergica, la utilizacion de dicha preparacion para laobtencion de medicamentos y el procedimiento para preparar dichos medicamentos
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
SI1185272T1 (en) Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
PL364936A1 (pl) Sposoby leczenia zaburzeń psychicznych z zastosowaniem bioaktywnych metabolitów gepironu
WO2004010936A3 (en) Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
MD523G2 (ro) Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
EP1256344A4 (en) REMEDIES FOR ENDOTHELIN-INDUCED DISEASES
AR015966A1 (es) Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
CA2464420A1 (en) Dosage unit comprising a prostaglandin analog for treating constipation
DE50211929D1 (en) Pyrimidinderivate
RU2002118304A (ru) Способ подавления чувства страха
PE20011004A1 (es) Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
ES2089974A1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
HUT70196A (en) New 2-[4-(4-azolyl-butyl)-1-piperazinyl] derivatives, process for producing them and their use in pharmaceutical compositions
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
MY143571A (en) Eplerenone crystalline form
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
DE3867042D1 (de) Pharmazeutische praeparate.
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.